Streetbeat News

Earnings

ATKR

Atkore has approved a new quarterly dividend program and anticipates declaring and paying its first quarterly cash dividend in the first quarter of fiscal year 2024, following the earnings announcement.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 11:10 am

ATKR

Atkore provided financial guidance for FY24, projecting net sales to range between $3.50B and $3.65B, compared to the estimated $3.61B. The company also forecasts adjusted EPS to be between $16.00 and $17.00, versus the estimated $16.47.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 11:07 am

MTBL

Moatable (NYSE:MTBL) reported a 10.78% increase in Q3 sales to $13.29M from $12.00M in the same period last year. The company also reported an adjusted net income of $43K, a significant improvement from a loss of $(1.93)M year-over-year.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 11:06 am

ATKR

Atkore (NYSE:ATKR) reported Q4 earnings with an EPS of $4.21, beating estimates by 3.19% but with a revenue decrease from the previous year. Last quarter's EPS beat was followed by a 3.83% share price drop.

Portfolio Pulse from Benzinga Insights

November 17, 2023 | 11:05 am

ATKR

Atkore (NYSE:ATKR) reported Q4 adjusted EPS of $4.21, surpassing the $4.08 estimate, but experienced a 23.73% decrease from last year's $5.52. Sales reached $869.89M, falling short of the $920.42M estimate and marking a 15.46% decline from the previous year.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 11:01 am

NOC

Northrop Grumman Corp (NYSE:NOC) is in advanced talks to produce 120mm tank ammunition in Poland, aiming to expand its European defense production capacity. CEO Kathy J. Warden is seeking the right industrial partners and contract structures. The state-owned PGZ armaments group's Mesko is finalizing negotiations for an offset agreement related to Poland's Abrams tanks purchase, which includes production of ammunition for Bushmaster guns. Northrop Grumman reported a 9% sales growth in Q3 FY23, with a backlog of $83.9 billion. NOC shares saw a slight decrease of 0.24% in the last trading session.

Portfolio Pulse from Lekha Gupta

November 17, 2023 | 10:46 am

AIRE

AMAT

ATGL

BABA

BIDU

CHPT

JD

ZTO

ChargePoint Holdings, Inc. (NYSE:CHPT) reported preliminary Q3 revenue of $108 million to $113 million, significantly below the expected $150 million to $165 million, and anticipates a non-cash impairment charge of $42 million, leading to a negative GAAP gross margin of 21% to 23%. The company also announced a CEO transition, appointing Rick Wilmer as the new president and CEO. ChargePoint shares dropped 24.3% in pre-market trading. Other stocks such as ATGL, AMAT, AIRE, ZTO, BABA, JD, and BIDU also experienced pre-market losses following various financial results and market movements.

Portfolio Pulse from Lisa Levin

November 17, 2023 | 10:13 am

AZN

AstraZeneca's Truqap, in combination with Faslodex, has been approved by the FDA for HR-positive, HER2-negative advanced or metastatic breast cancer with specific biomarker alterations. The approval follows the CAPItello-291 Phase III trial results, which showed a 50% reduction in disease progression or death compared to Faslodex alone.

Portfolio Pulse from Charles Gross

November 17, 2023 | 10:12 am

HUIZ

Huize Holding Limited (NASDAQ:HUIZ) reported a decrease in Q3 sales to $40.08M, down 18.95% from $49.45M YoY. However, the company saw a positive shift in its adjusted net profit, reporting $2.5M compared to a net loss in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 9:05 am

TSLA

Elon Musk, CEO of Tesla Inc (NASDAQ:TSLA), suggested the possibility of merging Neuralink's brain-computer interface technology with Tesla's Optimus bot to create advanced bionic limbs for amputees. Musk believes that this combination could result in artificial limbs that feel completely natural. This idea was previously discussed during Neuralink's second-quarter earnings call and again when Neuralink began recruiting for its first human clinical trial.

Portfolio Pulse from Anan Ashraf

November 17, 2023 | 8:54 am